• 1.

    Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185–93.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 2.

    Sen P, Yamana TK, Kandula S, Galanti M, Shaman J. Burden and characteristics of COVID-19 in the United States during 2020. Nature. 2021;598(7880):338–41.

    CAS 

    Google Scholar
     

  • 3.

    Chen S, Prettner K, Kuhn M, Bloom DE. The economic burden of COVID-19 in the United States: Estimates and projections under an infection-based herd immunity approach. J Econ Ageing. 2021;20:100328.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 4.

    WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 3 Nov 2021.

  • 5.

    Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 6.

    Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725–35.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–94.

    PubMed 

    Google Scholar
     

  • 8.

    Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355–71.

    CAS 
    PubMed 

    Google Scholar
     

  • 9.

    Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS ONE. 2021;16(3):e0248281.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 10.

    Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;25:1–8.


    Google Scholar
     

  • 11.

    Cho SI, Yoon S, Lee H-J. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. Sci Rep. 2021;11(1):6375.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 12.

    Lee KW, Yap SF, Ngeow YF, Lye MS. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(7):3554.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11:6282.


    Google Scholar
     

  • 14.

    Liang M, Luo N, Chen M, Chen C, Singh S, Singh S, et al. Prevalence and mortality due to COVID-19 in HIV Co-infected population: a systematic review and meta-analysis. Infect Dis Ther. 2021;10(3):1267–85.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 15.

    SeyedAlinaghi S, Karimi A, MohsseniPour M, Barzegary A, Mirghaderi SP, Fakhfouri A, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021;9(4):1160–85.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 16.

    de Medeiros KS, da Silva LAS, de Macêdo LT, Sarmento AC, Costa APF, Eleutério JJ, et al. Potential impact of the COVID-19 in HIV-infected individuals: a systematic review impact of the COVID-19 in HIV-infected individuals. Rev Assoc Med Bras. 2021;67:127–56.


    Google Scholar
     

  • 17.

    Mellor MM, Bast AC, Jones NR, Roberts NW, Ordóñez-Mena JM, Reith AJM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021;35(4):F1-10.

    CAS 
    PubMed 

    Google Scholar
     

  • 18.

    UNAIDS data 2020. https://www.unaids.org/en/resources/documents/2020/unaids-data. Accessed 16 May 2021.

  • 19.

    Ambrosioni J, Blanco JL, Reyes-Urueña JM, Davies M-A, Sued O, Marcos MA, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8(5):e294-305.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 20.

    HIV/AIDS. WHO | Regional Office for Africa. https://www.afro.who.int/health-topics/hivaids. Accessed 3 Nov 2021.

  • 21.

    Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570(7760):189–93.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 22.

    Richman DD. Normal physiology and HIV pathophysiology of human T-cell dynamics. J Clin Invest. 2000;105(5):565–6.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 23.

    Kouanfack OSD, Kouanfack C, Billong SC, Cumber SN, Nkfusai CN, Bede F, et al. Epidemiology of opportunistic infections in HIV infected patients on treatment in accredited HIV treatment centers in Cameroon. Int J MCH AIDS. 2019;8(2):163–72.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 24.

    Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–54.

    CAS 
    PubMed 

    Google Scholar
     

  • 25.

    Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049–55.


    Google Scholar
     

  • 26.

    Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19). Accessed 30 Apr 2020.

  • 27.

    Joanna MJ, Institute B. Critical appraisal checklist for prevalence. Studies. 2017;2017:7.


    Google Scholar
     

  • 28.

    critical-appraisal-tools – Critical Appraisal Tools | Joanna Briggs Institute. https://jbi.global/critical-appraisal-tools. Accessed 2 Nov 2021.

  • 29.

    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 30.

    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–29.


    Google Scholar
     

  • 31.

    Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. INT. 2021;64(1):36–47.

    CAS 

    Google Scholar
     

  • 32.

    Costenaro P, Minotti C, Barbieri E, Giaquinto C, Donà D. SARS-CoV-2 infection in people living with HIV: a systematic review. Rev Med Virol. 2021;31(1):1–12.

    CAS 
    PubMed 

    Google Scholar
     

  • 33.

    Choy K-T, Wong AY-L, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 34.

    Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–41.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 35.

    Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8:37.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 36.

    Characterizing Covid-19 presentation and clinical outcomes in HIV patients in the US. https://www.natap.org/2021/CROI/croi_109.htm. Accessed 16 May 2021.

  • 37.

    COVID-19 in hospitalized HIV-positive and HIV-negative patients: a matched study [Internet]. CROI Conference. https://www.croiconference.org/abstract/covid-19-in-hospitalized-hiv-positive-and-hiv-negative-patients-a-matched-study/. Accessed 19 May 2021.

  • 38.

    Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19. Front Public Health. 2020;8:418.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 41.

    Falutz J, Brañas F, Erlandson KM. Frailty: the current challenge for aging people with HIV. Curr Opin HIV AIDS. 2021;16(3):133–40.

    PubMed 

    Google Scholar
     

  • 42.

    Ponatshego PL, Youssouf NF, Mosepele M. Current co-morbidities burden in patients living with HIV in low- and middle-income countries. Curr Opin HIV AIDS. 2021;16(3):163–7.

    PubMed 

    Google Scholar
     

  • 43.

    Justiz Vaillant AA, Naik R. HIV-1 Associated Opportunistic Infections. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021. http://www.ncbi.nlm.nih.gov/books/NBK539787/. Accessed 3 Nov 2021.

  • 44.

    Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 45.

    Melo AKG, Milby KM, Caparroz ALMA, Pinto ACPN, Santos RRP, Rocha AP, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis. PLoS ONE. 2021;16(6):e0253894.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Chen LYC, Quach TTT. COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe. 2021;2(2):e49-50.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 47.

    Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 48.

    5th Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH). https://www.bhiva.org/AnnualConference2021. Accessed 3 Nov 2021.

  • 49.

    Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome. J Endocrinol Invest. 2021;44(5):951–6.

    CAS 
    PubMed 

    Google Scholar
     

  • 50.

    Hariyanto TI, Rosalind J, Christian K, Kurniawan A. Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis. South Afr J HIV Med. 2021;22(1):1220.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)